IMRX (Immuneering) ROE % Adjusted to Book Value : -70.26% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immuneering ROE % Adjusted to Book Value?

Immuneering's ROE % for the quarter that ended in Sep. 2024 was -94.15%. Immuneering's PB Ratio for the quarter that ended in Sep. 2024 was 1.34. Immuneering's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -70.26%.

Immuneering ROE % Adjusted to Book Value Historical Data

The historical data trend for Immuneering's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuneering ROE % Adjusted to Book Value Chart

Immuneering Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

-18.40

-32.48

-22.42

Immuneering Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-21.29	-26.05	-62.03	-136.26	-70.26

Competitive Comparison of Immuneering's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Immuneering's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuneering's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuneering's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Immuneering's ROE % Adjusted to Book Value falls into.

Immuneering ROE % Adjusted to Book Value Calculation

Immuneering's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-53.36%	/	2.38
	=	-22.42%

Immuneering's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-94.15%	/	1.34
	=	-70.26%

Immuneering ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Immuneering's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuneering Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuneering Corp (NAS:IMRX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, Second Floor, Cambridge, MA, USA, 02142

Website

https://www.immuneering.com

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Executives

Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Harold Eugene Brakewood	officer: Chief Business Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Mallory Morales	officer: Vice President, Finance	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Peter Feinberg	director	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Leah R Neufeld	officer: Chief People Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Brett Matthew Hall	officer: Chief Scientific Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Benjamin J. Zeskind	director, 10 percent owner, officer: President and CEO	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Ann E Berman	director	255 STATE STREET, BOSTON MA 02109
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Michael Bookman	officer: General Counsel and Secretary	C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142
Biren Amin	officer: CFO, Treasurer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142
Scott Barrett	officer: Chief Medical Officer	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142